MedPath

Fudan University

Fudan University logo
🇨🇳China
Ownership
Private
Established
1905-01-01
Employees
1K
Market Cap
-
Website
http://www.fudan.edu.cn

Singlera Genomics' GutSeer Assay Achieves 81.5% Sensitivity in Detecting Early-Stage Gastrointestinal Cancers

Singlera Genomics and Fudan University's Zhongshan Hospital published results from the GUIDE prospective cohort study in Molecular Cancer, demonstrating their GutSeer assay's ability to detect five major gastrointestinal cancers through a simple blood test.

Physical Activity in Childhood Linked to Better Mental Health and Cognitive Function in Adolescence

Finnish longitudinal study reveals children with higher physical fitness levels develop better cognitive abilities and experience lower rates of depression and stress as teenagers.

Phase 2 Trial Shows Promise: Serplulimab-HLX04 Combination Safe for Advanced Liver Cancer

A phase 2 trial demonstrates manageable safety profile of serplulimab combined with bevacizumab biosimilar HLX04 as first-line treatment for advanced hepatocellular carcinoma.

Mixed Results for Immunotherapy in Early Triple-Negative Breast Cancer

The NSABP B-59 trial showed that adding atezolizumab to neoadjuvant chemotherapy did not significantly improve event-free survival in stage II-III TNBC.

Wegovy Enters Chinese Market as Obesity Rates Rise

Wegovy, a weight-loss drug containing semaglutide, has been introduced in China, offering a new treatment option for the country's increasing obese population.

© Copyright 2025. All Rights Reserved by MedPath